Outcome of Board Meeting held on September 22, 2025
Awaiting price reaction for this filing.
The board approved audited standalone and consolidated FY25 results (year ended March 31, 2025). Standalone revenue from operations rose to ₹10,016 lakhs (vs ₹6,088 lakhs last year), but the company still posted a loss of ₹1,013 lakhs with fully eroded net worth of (₹38,820) lakhs. On a consolidated basis, the company swung to a profit of ₹11,502 lakhs (vs a ₹41,603 lakh loss), helped by a ₹15,431 lakh reversal of impairment on film advances (new GLOBUS ENTE deal), a ₹2,303 lakh profit on sale of office premises, and ₹2,500 lakhs received from an arbitration award. Statutory auditors Haribhakti & Co. LLP issued modified (qualified) opinions on both sets of results, flagging long-overdue trade receivables of over ₹25,000 lakhs from related group entities (Eros Worldwide FZE, Eros International UK, Eros International USA), pending RBI approvals, ongoing SEBI Show Cause Notices and Enforcement Directorate search operations, and non-availability of subsidiary CYPPL financials. Management explicitly flagged going-concern uncertainty due to fully eroded standalone net worth and prior defaults on statutory dues. The board also cleared the 31st AGM notice, e-voting facility, book closure dates, and appointed C R Bhagwat as scrutinizer.
Multiple red flags for shareholders — qualified audit opinions, a going-concern warning, distressed standalone balance sheet, and unresolved SEBI/ED probes. The consolidated profit turnaround is largely driven by one-time items (impairment reversal, asset sale, arbitration receipt) rather than steady operations, so the underlying business remains weak.